Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Diseases 1

Interventions

exemestane 4entinostat 4Fulvestrant 4ribociclib 3palbociclib 3abemaciclib 3Anastrozole 3Trastuzumab 2Letrozole 2Gonadotropin-Releasing Hormone 2AZD9833 2tucatinib 1trastuzumab deruxtecan 1taxane 1pertuzumab 1pembrolizumab 1ipatasertib 1figitumumab 1elacestrant 1dactolisib 1atezolizumab 1Watchful Waiting 1Trabectedin 1Tamoxifen 1STX-478 1RAD1901 1Paclitaxel 1Metformin 1Lapatinib 1Imlunestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Breast Diseases × STX-478 × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡